CHFS - CHF Solutions +7% after Aquadex therapy shows benefit in heart failure treatment

CHF Solutions (CHFS) announces data from a retrospective study supporting the benefit of Aquadex therapy in the treatment of heart failure. These data were presented at the 24th Annual Scientific Meeting of Heart Failure Society of America. The study enrolling 335 patients treated with the Aquadex FlexFlow System, compared previous RCT trials with ultrafiltration ((UF)) and demonstrated that UF compares favorably in reducing heart failure ((HF)) rehospitalizations, renal function response, and weight/volume loss. Specific results included:Substantial mean fluid removal (14.58 liters) and weight loss (15.63 lbs), which was sustained at 1-2 weeks post follow-up.Improvement in reduced HF rehospitalization rates at 30, 90 days, and 1 year of 12.4%, 14.9%, 27.3% respectively.Mean serum creatinine (sCr) increase of +0.07-0.11 mg/dl at time of stopping therapy, discharge, and follow up.On average, patients had 1.74 fewer hospitalizations for HF in the year following UF when compared to the year preceding UF.Major bleeding, defined as requiring

For further details see:

CHF Solutions +7% after Aquadex therapy shows benefit in heart failure treatment